ApoA-I Data Presented at European Society of Cardiology Congress

Calgary, Canada (ots/PRNewswire) -

- Multiple Presentations Included Resverlogix Data

- TSX Exchange Symbol: RVX

Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is
pleased to announce that Dr. Norman Wong presented key clinical data
pertaining to its lead compound, RVX-208, at the European Society
Cardiology (ESC) 2008 Congress in Munich. The presentation titled
"RVX-208 a novel small molecule that increases apolipoprotein A-I
enters into human clinical trials" was delivered on August 31, 2008.
In addition to this presentation, other important data relating to
RVX-208 from Resverlogix's extensive data portfolio was presented by
Dr. Jacques Genest of McGill University and Dr. Stephen Nicholls of
the Cleveland Clinic, at the same conference.

"Over the past year, the scientific community has pushed to the
forefront the importance of a small molecule in the form of an oral
tablet that significantly increases ApoA-I production, HDL
functionality and thereby treats atherosclerosis cardiovascular
disease," stated Dr. Jan Johansson, Senior Vice President Medical
Affairs Resverlogix. Johansson further added, "The ESC is a well
regarded scientific meeting as well as one of the largest with an
estimated 25,000 participants. We are pleased to have presented our
data to this esteemed audience."

Apolipoprotein A-I (ApoA-I), the main component of high-density
lipoprotein (HDL) represent the body's natural defense system against
atherosclerosis by mediating reverse cholesterol transport, i.e.
transport of peripheral cholesterol including that of the vessel
wall to the liver for elimination from the body. In multiple human
and animal studies over- expression or repeated infusion of ApoA-I
inhibit progression and induce regression of atherosclerosis in
animals and humans.

RVX-208, a novel small molecule drug that facilitates endogenous
ApoA-I production, is positioned as an emerging drug that holds the
most promise for the treatment of atherosclerosis. RVX-208 is
designed to increase ApoA-I production and thereby raise HDL levels
thus enhancing HDL functionality to augment reverse cholesterol
transport.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in
the development of novel therapies for important global medical
markets with significant unmet needs. The NexVas(TM) program is the
Company's primary focus which is to develop novel small molecules
that enhance ApoA-I. These vital therapies address the grievous
burden of atherosclerosis and other important diseases such as acute
coronary syndrome, diabetes, Alzheimer's disease and other vascular
disorders. The Company's secondary focus is TGF- Beta Shield(TM), a
program that aims to address burgeoning grievous diseases, such as
cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock
Exchange (TSX:RVX). For further information please visit
http://www.resverlogix.com.

This news release may contain certain forward-looking statements
that reflect the current views and/or expectations of Resverlogix
Corp. with respect to its performance, business and future events.
Such statements are subject to a number of risks, uncertainties and
assumptions. Actual results and events may vary significantly. The
TSX Exchange does not accept responsibility for the adequacy or
accuracy of this news release.

For further information: Theresa Kennedy, VP, Corporate
Communications, Resverlogix Corp., Phone: +1-604-538-7072, Email:
Theresa@resverlogix.com; Sarah Zapotichny, Manager, Investor
Relations, Resverlogix Corp., Phone: +1-403-254-9252, Email:
Sarah@resverlogix.com

Website: http://www.resverlogix.com

ots Originaltext: Resverlogix Corp.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information: Theresa Kennedy, VP, Corporate
Communications, Resverlogix Corp., Phone: +1-604-538-7072, Email:
Theresa@resverlogix.com; Sarah Zapotichny, Manager, Investor
Relations, Resverlogix Corp., Phone: +1-403-254-9252, Email:
Sarah@resverlogix.com